Dasatinib monohydrate
Cat. No.：YN280182
| 产品名称: | Dasatinib monohydrate |
| CAS No.: | 863127-77-9 |
| Chemical Name: | N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate (9CI); BMS 35482503; |
| Synonyms: | BMS-354825 monohydrate |
| 分子量: | 506.02 |
| 分子式: | C22H28ClN7O3S |
| SMILES: | CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO.O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Dasatinib (BMS-354825) monohydrate 是一种具有口服活性的，ATP 竞争性的，双重Src/Bcr-Abl抑制剂，具有有效的抗肿瘤活性。对Src和Bcr-Abl的Ki值分别为 16 pM 和 30 pM。Dasatinib monohydrate 抑制Bcr-Abl和Src的IC50分别为 <1.0 nM 和 0.5 nM。Dasatinib monohydrate 还诱导凋亡 (apoptosis) 和自噬 (autophagy)。 |
| IC50和靶点: | [{name:"Bcr-Abl:1.0 nM (IC50)"},{name: "Src:0.5 nM (IC50)"},{name: "lck:0.4 nM (IC50)"},{name: "yes:0.5 nM (IC50)"},{name: "c-kit:5.0 nM (IC50)"},{name: "PDGFRβ:28 nM (IC50)"},{name: "p38:100 nM (IC50)"},{name: "Her1:180 nM (IC50)"},{name: "Her2:710 nM (IC50)"},{name: "FGFR-1:880 nM (IC50)"},{name: "MEK:1700 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Couchman, L., et al.: Anal. Bioanal. Chem., 403, 1685 (2012)
